Rebel Fund
Jonathan Hirsch serves as the Chief Strategy and Growth Officer at Paradigm, focusing on enhancing equitable access to clinical trials and reducing the burden on physicians involved in clinical research. In addition to this role, Jonathan co-founded Synapticure Inc. and functions as an investor and advisory board chair there, while also investing in Arbital Health, Frame, Thyme Care, Forta, and other companies. Jonathan advises Viz.ai and Osmind, and provides insights to Freenome as an advisor on Real World Evidence and Data Platforms. With a background in Biological Sciences from Stanford University and degrees in Biology and Political Science from the University of Chicago, Jonathan combines educational expertise with a commitment to building innovative companies in the healthcare sector.
This person is not in any teams
Rebel Fund
Rebel (www.rebelfund.vc) aims to invest in the best 0.1% of the 40,000+ tech startups that apply each year to Y Combinator, the #1 accelerator in the world with 80+ unicorns and $600B+ in portfolio company value. The fund’s due diligence and investing decisions are made by a team of accomplished Y Combinator alumni who have founded companies now valued over $85B in aggregate, invested in 200+ startups, and generated top-decile portfolio returns. Rebel utilizes a proprietary machine-learning algorithm called Rebel Theorem to help validate and screen potential investments, building a diversified portfolio of top Y Combinator startups that is statistically powered to outperform.